OCS Stock Summary and Trading Ideas (Oculis Holding Ag - | NASDAQ:OCS)

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding Ag - trades on the NASDAQ stock market under the symbol OCS.

As of January 14, 2026, OCS stock price climbed to $23.66 with 211,982 million shares trading.

OCS has a beta of 0.59, meaning it tends to be less sensitive to market movements. OCS has a correlation of 0.04 to the broad based SPY ETF.

OCS has a market cap of $1.37 billion. This is considered a Small Cap stock.

Last quarter Oculis Holding Ag - reported $303,761 in Revenue and -$.40 earnings per share. This beat revenue expectation by $53,761 and exceeded earnings estimates by $.10.

The top ETF exchange traded funds that OCS belongs to (by Net Assets): SBIO, SMLV.

OCS has underperformed the market in the last year with a return of +5.7%, while SPY returned +20.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in OCS shares. However, OCS has outperformed the market in the last 3 month and 2 week periods, returning +12.7% and +18.7%, while SPY returned +4.4% and +0.5%, respectively. This indicates OCS has been having a stronger performance recently.

OCS support price is $22.15 and resistance is $23.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCS shares will trade within this expected range on the day.